How should highly experimental gene therapies be tested safely? Three reported deaths, including those of two children, have intensified scrutiny of trial monitoring, transparency and regulatory safeguards.
How safely are experimental gene-editing and cell therapies being tested?
The reported deaths of three patients in separate trials in China have raised concerns about patient protection, transparency and clinical-trial oversight.
The patients included two children and an adult man. The deaths occurred between May 2025 and March 2026 in investigator-initiated trials led by researchers or medical institutions rather than through the conventional commercial drug-development pathway.
The cases became widely known only months later, prompting questions about how serious adverse events are investigated, disclosed and communicated to regulators and the scientific community (1✔ ✔Trusted Source
Three deaths in China shake trust in the country’s speedy clinical trial system
Advertisement
Three Patients Died After Experimental Treatments
The first reported case involved a 6-year-old girl with Snijders Blok-Campeau syndrome, a rare neurodevelopmental condition. She died seven days after receiving an experimental gene-editing treatment at Xinhua Hospital in Shanghai in May 2025.
The therapy was reportedly delivered into the cerebrospinal fluid. The hospital’s ethics board later determined that her death was definitely related to the experimental treatment (1✔ ✔Trusted Source
Three deaths in China shake trust in the country’s speedy clinical trial system
A second case involved a boy with Duchenne muscular dystrophy who received an experimental CRISPR-based treatment developed by HuidaGene Therapeutics. He died in August 2025 after developing acute respiratory distress syndrome during a severe immune reaction following administration of a high dose of the viral-vector therapy.
The death was publicly disclosed by the company in August 2026 after questions from reporters. The child was reportedly the fourth participant treated and received the highest dose administered in the study.
The third case involved a man in his 50s with scleroderma who died in March 2026 after receiving an experimental in-vivo CAR-T therapy developed by RiboX Therapeutics.
RiboX had announced US Food and Drug Administration clearance to begin testing the treatment in the United States shortly before the death became public. Public reports have not established that the therapy caused his death, making further investigation important before conclusions are drawn.
Advertisement
Gene and Cell Therapies Can Trigger Serious Reactions
Gene therapies use delivery systems that often modified viruses to carry genetic material into a patient’s cells. Although these vectors are engineered for medical use, the immune system may still recognise them as foreign and produce a powerful inflammatory response.
High doses may increase this risk because they expose the body to a larger quantity of the vector. In the Duchenne muscular dystrophy case, the child reportedly developed acute respiratory distress syndrome during a severe immune reaction.
Acute respiratory distress syndrome causes inflammation and fluid accumulation in the lungs, severely limiting the transfer of oxygen into the bloodstream. It can progress rapidly and become life-threatening.
Gene editing introduces additional uncertainties because it is intended to alter genetic material. Researchers must assess whether the edit occurs at the intended site, whether unintended genetic changes occur and whether the delivery method produces damage of its own.
CAR-T and other cell-based therapies may also cause intense immune reactions. The risks can vary according to the treatment platform, dose, route of administration, targeted disease and individual patient factors.
Advertisement
Independent Safety Monitoring Is Under Scrutiny
The deaths have attracted particular attention because they occurred in investigator-initiated trials. Such studies can support early medical innovation, especially for rare diseases with few treatment options, but they require clear safeguards because the treatments may have limited previous human testing.
Questions have been raised about whether some trials had adequate independent safety monitoring. According to reporting cited by Health and Me, the HuidaGene study did not have an independent data and safety monitoring board.
A data and safety monitoring board reviews accumulating trial information independently of the investigators. It may recommend changing, pausing or ending a study when serious harm emerges or when the risk-benefit balance becomes unacceptable.
The absence of such a board does not by itself prove that a study was improperly conducted. However, independent review is particularly important in small, early-stage trials involving children, high doses or irreversible interventions.
Prompt disclosure is also essential. Delayed reporting can prevent other researchers, ethics committees and regulators from learning about risks that may affect similar trials or future participants.
US Lawmakers Seek Greater Scrutiny of Trial Data
The reported deaths have prompted US Representatives John Moolenaar and Ben Cline to ask the FDA to apply greater scrutiny to clinical-trial data produced in China.
They called on the agency to stop accepting data from Chinese trial sites for US drug applications unless the sites had been inspected recently. In their letter, the lawmakers argued that treatments approved in the United States should be supported by data produced with scientific rigor, ethical safeguards and accountability (1✔ ✔Trusted Source
Three deaths in China shake trust in the country’s speedy clinical trial system
Site location alone does not determine whether research is reliable. Clinical trials conducted in any country can produce valuable evidence when they follow rigorous ethical, scientific and regulatory standards.
The central concern is whether trial participants are adequately protected, serious adverse events are independently investigated and safety information is disclosed quickly and transparently.
Gene and cell therapies continue to offer potential treatments for serious and previously untreatable diseases. However, the reported deaths show that scientific promise must be accompanied by cautious dose escalation, independent monitoring, timely reporting and clear regulatory oversight.
References:
- Three deaths in China shake trust in the country’s speedy clinical trial system(https://endpoints.news/three-deaths-in-china-shake-trust-in-its-speedy-clinical-trial-system/)
Source-Medindia